cigna glp-1 news Why is capping cost increases for pricey weight loss drugs Cigna drops coverage of GLP-1

According to a report on 06/03/2026, Cigna said that beginning 07/01/2026 it will discontinue coverage of GLP-1 weight-loss medications, including Novo Nordisk's Wegovy and Eli Lilly's Zepbound, for roughly 67,700 employees in its U.S

With GLP-1 drugs suppressing appetite, its no surprise that users are shifting their dining habits

A high-fiber diet and plant-based foods can promote the growth of beneficial bacteria in the gut microbiome, while high-fat and high-sugar diets have been linked to dysbiosis (Koh et al., 2016

WADA 2026 Prohibited List Status (Section S0) BPC-157 is named explicitly on the World Anti-Doping Agency 2025 and 2026 Prohibited Lists under section S0 (Non-Approved Substances)